APA (7th ed.) Citation

J, T., R, W., M, N., JML, E., T, I., M, S., . . . K, T. (2026). ASO Visual Abstract: TRIM37 Expression is Associated with Immune Suppression, Poor Response to Neoadjuvant Chemotherapy, and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. Annals of surgical oncology, 33(4), 3399. https://doi.org/10.1245/s10434-026-19108-z

Chicago Style (17th ed.) Citation

J, Tsuchida, Wu R, Nagahashi M, Ebos JML, Ishikawa T, Shimoda M, Wakai T, and Takabe K. "ASO Visual Abstract: TRIM37 Expression Is Associated with Immune Suppression, Poor Response to Neoadjuvant Chemotherapy, and Worse Survival in ER-Positive/HER2-Negative Breast Cancer." Annals of Surgical Oncology 33, no. 4 (2026): 3399. https://doi.org/10.1245/s10434-026-19108-z.

MLA (9th ed.) Citation

J, Tsuchida, et al. "ASO Visual Abstract: TRIM37 Expression Is Associated with Immune Suppression, Poor Response to Neoadjuvant Chemotherapy, and Worse Survival in ER-Positive/HER2-Negative Breast Cancer." Annals of Surgical Oncology, vol. 33, no. 4, 2026, p. 3399, https://doi.org/10.1245/s10434-026-19108-z.